Qurient Co., Ltd.

KOSDAQ:A115180 Stock Report

Market Cap: ₩124.1b

Qurient Valuation

Is A115180 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A115180 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A115180's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A115180's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A115180?

Other financial metrics that can be useful for relative valuation.

A115180 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10x
Enterprise Value/EBITDA-4.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does A115180's PS Ratio compare to its peers?

The above table shows the PS ratio for A115180 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average25.4x
A365270 curacleltd
15.6xn/a₩90.5b
A083790 CG Invites
53.2xn/a₩199.1b
A317690 QuantaMatrix
19.4xn/a₩67.7b
A226950 OliX Pharmaceuticals
13.4xn/a₩209.4b
A115180 Qurient
13.8xn/a₩124.1b

Price-To-Sales vs Peers: A115180 is good value based on its Price-To-Sales Ratio (13.8x) compared to the peer average (25.4x).


Price to Earnings Ratio vs Industry

How does A115180's PE Ratio compare vs other companies in the KR Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a50.2%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a50.2%
n/an/an/a
No more companies

Price-To-Sales vs Industry: A115180 is expensive based on its Price-To-Sales Ratio (13.8x) compared to the KR Biotechs industry average (10.4x).


Price to Sales Ratio vs Fair Ratio

What is A115180's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A115180 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio13.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A115180's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.